Trial Profile
Evaluation of the effects and plasma concentration of the potent platelet inhibitor ticagrelor, after crushed and non-crushed intake, after semi-urgent coronary bypass and in patients after cardiac arrest.
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 09 Feb 2023
Price :
$35
*
At a glance
- Drugs Ticagrelor (Primary)
- Indications Angina pectoris; Myocardial infarction
- Focus Pharmacokinetics; Therapeutic Use
- 06 May 2021 Status changed from recruiting to completed.
- 16 Jan 2015 Planned End Date changed from 28 Nov 2016 to 1 Jan 2017, according to ClinicalTrials.gov record.
- 16 Jan 2015 Planned primary completion date changed to 1 Jul 2016, according to ClinicalTrials.gov record.